Shares of Apollomics, Inc. (NASDAQ:APLM – Get Free Report) dropped 4% during mid-day trading on Monday . The company traded as low as $9.45 and last traded at $9.50. Approximately 16,190 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 93,693 shares. The stock had previously closed at $9.90.
Apollomics Trading Down 4.0 %
The business has a fifty day simple moving average of $8.07 and a 200 day simple moving average of $10.48.
Apollomics Company Profile
Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.
Featured Articles
- Five stocks we like better than Apollomics
- What is a Secondary Public Offering? What Investors Need to Know
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- The Role Economic Reports Play in a Successful Investment Strategy
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Apollomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollomics and related companies with MarketBeat.com's FREE daily email newsletter.
